PPIL1 expression based on
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Comparison | Statistical significance |
Normal-vs-Primary | 3.83026943495679E-14 |
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Stage1 |
2.87689999600715E-08 |
Normal-vs-Stage2 |
3.568800E-04 |
Normal-vs-Stage3 |
N/A |
Normal-vs-Stage4 |
2.024000E-03 |
Stage1-vs-Stage2 |
1.993550E-01 |
Stage1-vs-Stage3 |
N/A |
Stage1-vs-Stage4 |
8.355200E-01 |
Stage2-vs-Stage3 |
N/A |
Stage2-vs-Stage4 |
3.635000E-01 |
Stage3-vs-Stage4 |
N/A |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Caucasian |
1.35558231306732E-12 |
Normal-vs-AfricanAmerican |
3.727600E-01 |
Normal-vs-Asian |
5.344400E-02 |
Caucasian-vs-AfricanAmerican |
5.058200E-01 |
Caucasian-vs-Asian |
2.488600E-01 |
AfricanAmerican-vs-Asian |
9.070200E-01 |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Male |
5.0258999995112E-07 |
Normal-vs-Female |
1.966200002812E-08 |
Male-vs-Female |
4.578800E-01 |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Patient BMI information is not available for 1 sample.
Descriptions |
Normal weight |
BMI greater than equal to 18.5 and BMI less than 25 |
Extereme weight |
BMI greater than equal to 25 and BMI less than 30 |
Obese |
BMI greater than equal to 30 and BMI less than 40 |
Extreme Obese |
BMI greater than 40 |
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Normal_Weight |
1.193440E-04 |
Normal-vs-Extreme_Weight |
6.58779999995751E-07 |
Normal-vs-Obese |
7.426400E-04 |
Normal-vs-Extreme_Obese |
N/A |
Normal_Weight-vs-Extreme_Weight |
6.934200E-01 |
Normal_Weight-vs-Obese |
3.199400E-01 |
Normal_Weight-vs-Extreme_Obese |
N/A |
Extreme_Weight-vs-Obese |
4.968000E-01 |
Extreme_Weight-vs-Extreme_Obese |
N/A |
Obese-vs-Extreme_Obese |
N/A |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Age(21-40Yrs) |
2.64580000131076E-08 |
Normal-vs-Age(41-60Yrs) |
2.016400E-04 |
Normal-vs-Age(61-80Yrs) |
8.17220002780061E-09 |
Normal-vs-Age(81-100Yrs) |
1.661590E-01 |
Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.837400E-01 |
Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.782800E-01 |
Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.439800E-01 |
Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.363800E-01 |
Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.717600E-01 |
Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.731600E-01 |
|
|
CHOL : Cholangiocarcinoma
Subtype descriptions |
Grade 1 | Well differentiated (low grade) |
Grade 2 | Moderately differentiated (intermediate grade) |
Grade 3 | Poorly differentiated (high grade) |
Grade 4 | Undifferentiated (high grade) |
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Grade 1 |
N/A |
Normal-vs-Grade 2 |
2.325400E-01 |
Normal-vs-Grade 3 |
3.099800E-01 |
Normal-vs-Grade 4 |
1.000000E+00 |
Grade 1-vs-Grade 2 |
N/A |
Grade 1-vs-Grade 3 |
N/A |
Grade 1-vs-Grade 4 |
N/A |
Grade 2-vs-Grade 3 |
2.949200E-01 |
Grade 2-vs-Grade 4 |
2.325400E-01 |
Grade 3-vs-Grade 4 |
3.099800E-01 |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 5 samples.
pathologic_N descriptions |
N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-N0 |
3.54429818827384E-11 |
Normal-vs-N1 |
9.002500E-03 |
N0-vs-N1 |
2.825400E-01 |
|
|